.INVESTIGATION FEATURE.06 August 2024.
A big randomized controlled trial along with cisgender girls highlights the challenges of faithfulness to a daily oral preexposure treatment regiment as well as illustrates that twice-yearly treatment of lenacapavir may sustain efficient HIV protection degrees over 6 months.